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The name dendritic cell (DC) was given by Steinman to describe the unusual cell type he saw in
spleen cell suspensions. This morphological description is not sufficient to specify the cell of so
much interest to immunologists; many cells can adopt a similar form. A useful functional definition
evolved as Steinman and colleagues explored the immunological properties of this novel cell type
(1). DCs were considered as antigen collecting and processing cells able to present antigen onMHC
molecules and efficiently activate even primary T-cells. Nowadays, immunologists would likely add
to this definition, a capacity to sense the context in which the antigen was collected, via receptors for
pathogen or damaged cell-derived material. Why might we need to go beyond the name “dendritic
cell” for cells with these well-understood functions? Some limitations of this single name arose early
in DC research. This article surveys some problems of definition encountered in past work from
our own laboratory. The problems we encountered arose from two sources, the first the discovery
of different DC subsets and the need to determine whether these represented different maturation
states or separate sub-lineages. The secondwas the difficulty in distinguishing theseDC subsets from
macrophages.
Our first hint that there could be distinct types of DCs came from our studies with Wu and
Ardavin on thymic T and DC development (2). We were surprised to find that a high proportion
of mouse thymic DCs stained with antibodies against characteristic T-cell markers, such as CD8α;
it was a relief to find they did not stain with antibodies against CD3 or the T-cell receptor! Pickup
of material from thymocytes was eliminated as an explanation. We then found a similar but less
frequent DC subset staining for surface CD8α among the DCs in mouse spleen and these DCs were
shown to express mRNA for CD8α (3). Others had already reported some staining of DCs with
anti-CD8; our work emphasized that these CD8+ DCs were a distinct population, CD8α expression
being positively correlated with expression of DEC205 but inversely correlated with expression of
other markers such as CD4, CD11b, and, as illustrated in Figure 1, SIRPα (4, 5).
Immunological interest in the CD8+ and CD8  DC subsets increased when it became apparent
from the work ofmany laboratories that these DCs differed in immunological functions. Differences
were apparent in the expression of toll-like and other microbial pattern recognition receptors, in
the cytokines produced on activation, in the fate of the T-cells they stimulated, in their capacity
to phagocytize dead cells, and in the processing of antigens for MHC class I versus MHC class II
presentation [reviewed in Ref. (7)]. The key findings from our laboratory were that the CD8+ DCs,
when appropriately stimulated, were the most potent producers of IL12p70 (8), and that the CD8+
DCs have a strong bias to cross-presenting exogenous antigens, both soluble and particulate, for
MHC class I presentation (9, 10).
An important issue became whether these functionally distinct DC types represented different
lineages, or were simply different maturation states within one very plastic lineage. There was direct
evidence, confirmed by us, that some CD8  DCs could on adoptive transfer, produce CD8+ DCs.
However, these CD8+ DCs proved to be generated from a small number of early members of the
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2671
Vremec and Shortman DC nomenclature, past and present
FIGURE 1 | Segregation of conventional DC subsets in mouse spleen.
Spleen CD11c+cDC were isolated, enriched, and gated as in Vremec et al. (5).
Staining for CD8α and SIRPα allows clear segregation into the DC1 (CD8+ DC)
and DC2 (CD8  DC) subsets. However, the DC2 population can be separated
into two further subsets by several surface markers, here Clec12A and ESAM as
demonstrated in Lewis et al. (6).
CD8+ DC lineage that had not yet acquired CD8α expression; the
bulk of CD8  DCs did not give rise to CD8+ DCs (11). Although
sequential maturation states were found within the CD8+ DC
lineage, with early forms lacking CD8α expression (12) and the
earliest stages lacking capacity for antigen cross-presentation (13),
therewas a clear developmental separation from the bulk of CD8 
DCs. A further distinct DC type in mouse spleen became evident
when the mouse equivalent of the human type 1 interferon-
producing plasmacytoid dendritic cell (pDC) was identified (14).
Although some pDCs expressed CD8α (15), they were clearly
a separate lineage from the CD8+ conventional DCs (cDCs).
Our subsequent work with Naik showed that spleen CD8+ DCs
and CD8  DCs represented separate cDC sub-lineages derived
via pre-DC populations from a bone marrow pro-DC or com-
mon dendritic cell precursor (CDP) (16–18). Thus, because of
differences in surface phenotype, immunological functions, and
developmental pathways, these two spleen cDC populations had
to be distinguished, and the terms CD8+ cDC and CD8  cDC
became current.
In line with the pioneering work of Salomon et al. (19) and
Anjuere et al. (20), we extended our analysis of DC subtypes from
mouse spleen to mouse lymph nodes (LNs) (4, 21). Spleen should
contain only what we termed the “lymphoid tissue resident” cDCs
whereas LNs should contain both these and the “migratory” cDC
type arriving via the lymph from other tissues. It was immediately
apparent that the level of DC heterogeneity was greater than in
spleen. One source of heterogeneity was the existence of different
activation states within even oneDC lineage. In particular, the DC
that hadmigrated even in steady state fromperipheral tissues such
as skin into LNsweremore activated than those remaining in skin,
and more activated than their lymphoid tissue resident counter-
parts; the DCs that had migrated expressed higher surface levels
of MHC class II and of co-stimulator molecules such as CD86.
Although they were first called “mature” DCs they proved to be
not fully activated but “semi-mature”; they were not producing
cytokines and were likely tolerogenic (22). A similar transforma-
tion termed “spontaneous activation” occurred when spleen cDCs
were isolated and placed in culture (23). In both cases, further
signals, such as given by microbial products interacting with TLR
ligands, were required to produce a fully active, cytokine secreting
immunogenic DC. However, even when these different activation
states were considered, further cDC subsets not found in spleen
were apparent, such as the epidermal Langerhans cell-derived LN
DCs. The full lineage complexity of LN has now been well delin-
eated by other laboratories, a notable finding being the existence
of a migratory form of the CD8+ DC lineage but lacking CD8α
expression, commonly termed as the CD103+ cDCs (24–26).
Our second problem with DC nomenclature arose as we
attempted to distinguish DCs from macrophages, a particularly
difficult exercise in inflamed tissues. It was also difficult to
relate the DC populations we isolated from steady state mouse
spleen with the DCs produced by culture of monocytes with
granulocyte-macrophage colony stimulating factor (GM-CSF), a
well-established model of DC generation (27). At that time, it
was generally assumed that all DCs and macrophages would be
bone marrow derived cells, with monocytes as the common late
precursor. Some questioned whether it was valid even to consider
DCs as a separate entity rather than as a macrophage variant (28).
We had some sympathy with this view, since in experiments with
Metcalf we had difficulty in segregating DCs from macrophages
in the peritoneal fluid from mice expressing high levels of GM-
CSF (29). Although cells with DC function and surface phenotype
could be segregated from macrophages at the extremes of the
distribution, there appeared to be a continuum of phenotypes
rather than two discrete populations. For us the clarification came
when, with Naik, the immediate precursor of the spleen cDC was
isolated and shown to be distinct from monocytes and unable
to produce macrophages (16). We termed these pre-DCs. This
led to the view that there were two different routes to cells with
DC antigen presenting function, one via monocytes and more
often found under conditions of inflammation, the other derived
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from CDP/pro-DC precursors in bone marrow then via pre-DC
to the types of DC found in steady state lymphoid tissue (17).
The culture model finally developed for generation of the type
of DCs found in steady state became bone marrow stimulated
with Flt3 ligand, rather that with GM-CSF (30, 31). Thus, the
developmental pathway leading to DC functions became a major
criterion for segregating and naming DC subtypes.
It was then possible to segregate DCs derived from mono-
cytes from the cDCs found in steady state spleen. However, it is
evident from the account above that our previous nomenclature
of the subsets of spleen cDCs based on CD8α expression was
inadequate. Certain pDC subsets also expressed CD8α. Early DCs
of “CD8+ cDC” lineage in spleen did not express CD8α. The
migratory version of the same lineage, the CD103+ DCs, did not
express it. And finally, CD8 was not expressed by human DCs. A
major advance was the demonstration in several laboratories of an
equivalent of themouse “CD8+ cDC” lineage within humanDCs,
and the finding that the chemokine receptor XCR1 and the C-type
lectin-like molecule Clec9A, rather than CD8, served as common
DC surface markers crossing this species barrier [commentary in
Ref. (32)]. The proposed designation of this DC subtype as DC1
overcomes the previous nomenclature problems (33).
In contrast to these advances in understanding the DC1 subset,
the CD8  CD11bhigh SIRPαhigh cDCs (designated as DC2) have
been less studied and still present nomenclature issues. We had
already separated spleen CD8  DCs into two subsets based on
CD4 expression (5), but the significance of this remains obscure.
Amore meaningful separation can now bemade based on surface
expression of Clec12A (DCAL2, MICL) versus DCIR2 or ESAM
(6, 34, 35). An example of such segregation is shown in Figure 1.
Importantly, these DC subsets differ in both developmental
requirements and immunological characteristics; formation of
DCIR2+ ESAMhigh Clec12A  DCs requires Notch2 signaling
and this subset selectively responds to flagellin and induces Th2
responses. Will these differences demand a further division into
DC2 and DC3 subtypes? Or will one of these, particularly the
Clec12A+ subset, prove to be part of the monocyte-derived
group? These questions require further work.
It is notable that ontogeny has led to a better understanding
and provided one logical basis for DC classification (33). Will
ontogeny be the best guide for DC nomenclature in future? We
can foresee one area where it may cause confusion. A proportion
of mouse pDCs and the CD8α-expressing subset of cDCs in
the mouse thymus have a potential route of development from
lymphoid rather than myeloid precursors (36, 37). These DC
types have D–J rearrangements in their Ig heavy chain genes, a
characteristic of lymphoid-origin cells (38). The extent to which
a lymphoid route contributes to their development in steady state
is still unclear, but the potential is there. Yet, the thymic CD8+
DCs are similar to the splenic CD8+ DCs of myeloid origin,
and pDCs developing from myeloid or lymphoid precursors have
similar surface phenotype and immunological functions. Should
they have separate names according to their developmental origin,
or should this “convergent” development lead to cells with the
same name? There may yet be fine differences in function that
eventually will be important to specify, but at present they are
called by the same name. One resolution of this paradox comes
from the likelihood that, despite the differences in bone marrow
precursor surface markers, a common molecular program for
pDC or for CD8+ cDC formation has been initiated, with tran-
scription factors that override any previous precursor orientation.
Considering ontological origin in terms of these final molecular
programs, rather than by the surface markers on the precur-
sor cells, should overcome the paradox resulting from apparent
convergent differentiation.
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